wellthy CARE™ – A Digital Health Intervention Platform for Pain Management and Remote Monitoring in Rheumatoid Arthritis Patients


Unbridged Care Gaps in Treatment with Traditional therapeutics–

  1. Growing Unmet Needs in Patients in RA
    • Despite the therapeutic advances for patients with RA, poor physical functioning, pain, comorbidity, depression, and anxiety remain persistent problems.1
    • The true severity reported of the pain and flares experienced between visits is mostly incorrect due to recall bias for the usual gap of 3-6 months in meeting the physician.
    • Due to the lengthy nature of the treatment cycle, adherence to the treatment often becomes an issue leading to patients experimenting with different therapy options.
  2. Rising Healthcare Burden:
    • With nearly 2.3 million individuals diagnosed with RA in Europe each year, annual direct and indirect management costs are estimated to be around €45 billion.2
    • 10% of RA patients use healthcare resources same as the remaining 90%, attributed to comorbidities and higher levels of chronic pain.3
    • Increased burden on family and society with the increased direct & indirect costs including treatment, work disability, and early retirement.4
  3. Growing Dissatisfaction with Current Line of Treatment:
    • 74% of patients with RA reported dissatisfaction with their treatment plans, and that their disease symptoms persisted despite active treatment with DMARDs.5
    • Nearly half of all the patients with RA would like more information and input in their treatment decisions.6
    • Given the pain and discomfort, patients find it difficult to abide by their physical therapy schedule.

Disease Journey with wellthy CARE

case-study-cover

Case Study

Seven Month Fast Track to Standalone Samd co-development for a Leading Speciality Pharma in a Rare Disease

Download Case Study

Adding Value to all Stakeholders

  • Making symptoms and inflammation management easy
  • Track signs of reduced/stopped disease activity
  • Improve physical function and improved overall activity scores
  • Maximized adherence to conventional synthetic DMARD or combination therapy
  • Management of side effects including nausea, ulcers, hair loss, skin rashes, etc.
  • Reduce joint damage progression and subsequently improve patients’ health-related quality of life (QoL)
  • Reduced difficulty in sleeping
  • Optimal therapy delivery through treatment adjustments/changes
  • Optimal resource utilization by enabling remote care and activating smart care workflows
  • Access to valuable insights from analyzing tons of patient data
  • Triaging for informed decision making and resource utilization
  • Passively monitor thousands of patients at the same time
  • Developing an early understanding of the drug in real-world post-initiation
  • Comprehensive side effect management and planning for adverse events
  • Improved patient diagnosis and treatment selection
  • Shorter time to market and fewer risks
  • Enhanced treatment penetration
  • Differentiation and innovation beyond current offerings

The wellthy CARE™ Engine

We understand the importance of a digital health platform for rare disease patients to actively monitor and improve their disease. This led us to build a solution that delivers:

patient-success2

Patient Success

Evidence-based, patient-centered, fits perfectly into your care management routine, addresses risk factors

dashboard1

Analytical Dashboard

Analyses patient data for enhanced monitoring

integration1

Seamless Integration

Supports API-based integration with electronic health records to support a contextual view of patient information

engagement1

Adoption and Engagement

Weather forecast, inbuilt reward & value system, gamification, & treatment personalization, health coach & regular check-ins

Exploring Co-Creation for Enhanced Patient Outcomes?

Our Multi-disciplinary team at Wellthy is constituted of medical experts, software developers, behavioral user-experience designers, compliance experts, and data scientists experienced in co-creating digital health solutions in varied therapeutic areas for top pharma companies around the globe.

Keeping the patient at the center, while using your experience in cancer therapy development and our expertise in building and developing a digital health solution, we can launch a novel oncology care solution that shows improved adoption and engagement.

Come Talk to us

References:

  1. https://www.hospitalmanagement.net/comment/unmet-needs-remain-in-rheumatoid-arthritis-for-patient-satisfaction-and-symptom-management/
  2. https://academic.oup.com/rheumap/article/4/2/rkaa041/5906574
  3. https://pubmed.ncbi.nlm.nih.gov/34511040/
  4. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1-12. doi: 10.2165/00019053-200422001-00002. PMID: 15157000.
  5. https://www.rheumatologyadvisor.com/home/topics/rheumatoid-arthritis/patient-reported-outcomes-unmet-needs-dissatisfaction-with-current-treatment-in-rheumatoid-arthritis/#:~:text=There%20are%20significant%20unmet%20needs,published%20in%20Rheumatology%20and%20Therapy
  6. “Management of Rheumatoid Arthritis”:https://assets.cwp.roche.com/f/126832/x/33f56ac851/management-of-ra-infographic.pdf